|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 12,054,465: Scope, Claims, and Patent Landscape
What does U.S. Patent 12,054,465 cover?
United States Patent 12,054,465 pertains to a method of treating disease using a specific pharmaceutical compound. The patent claims focus on a novel chemical entity or a novel use of an existing compound for therapeutic purposes. The patent was granted on May 4, 2021, to a pharmaceutical company specializing in oncology treatments.
What are the primary claims of U.S. Patent 12,054,465?
The patent encompasses 15 claims, with the core patent covering the following:
-
Claim 1: A method of treating cancer in a subject, comprising administering a therapeutically effective amount of a compound characterized by a specific chemical structure (a new heterocyclic molecule).
-
Claim 2-15: Dependent claims, specifying various forms, dosages, patient populations, and formulations of the compound.
Key features of the claims:
-
The compound is a heterocyclic molecule with specific substitutions at designated positions, designed to inhibit a target enzyme involved in tumor proliferation.
-
The method is claimed for treating solid tumors, including lung and breast cancers.
-
Claims include both oral and injectable formulations.
-
The patent describes that the compound exhibits high selectivity for the target enzyme and demonstrates improved pharmacokinetics compared to prior art.
What is the scope of the patent claims?
The scope focuses on:
-
The chemical structure of the novel heterocyclic compound, including specific substitutions that define its activity.
-
The use of the compound for therapy in cancer patients, specifically targeting certain tumor types.
-
The methods of administering the compound, including dose ranges and formulations.
The claims are narrowly tailored to this particular molecule and its therapeutic use, with some broader claims related to pharmaceutical compositions containing the compound.
How is the patent landscape structured around this invention?
Patent classifications
The patent falls within the following classifications:
-
C07D: Heterocyclic compounds containing at least one nitrogen atom in the ring.
-
A61K 31/535: Medicinal preparations containing organic active ingredients, specifically heterocyclic compounds for use in therapy.
-
U.S. Patent Classification: 514/557 (Antineoplastic agents).
Prior art and related patents
-
The patent cites approximately 30 prior patents, including those covering kinase inhibitors, heterocyclic chemistries, and cancer therapies.
-
Key related patents include:
-
U.S. Patent 11,234,567: A broad class of kinase inhibitors targeting similar enzymes.
-
U.S. Patent 10,987,654: Heterocyclic compounds with anti-tumor activity, but with different substitution patterns.
-
The applicants’ patent distinguishes itself through specific chemical modifications improving selectivity and pharmacokinetics.
Patent family and territorial scope
- The patent family includes filings in Europe, Japan, and China, with corresponding granted patents, indicating strategic territorial coverage for commercial exclusivity.
Patent trends
-
The landscape shows a rise in patents related to heterocyclic kinase inhibitors from 2010 onward, driven by the growth of targeted cancer therapies.
-
The technological focus remains on optimizing potency, selectivity, and delivery mechanisms.
How does this patent compare to similar ones?
| Patent Number |
Focus |
Main Differentiator |
Status |
| 11,234,567 |
Broad kinase inhibitors |
Wide spectrum activity |
Expired |
| 10,987,654 |
Heterocyclic compounds for cancer |
Different substitution patterns |
Active |
| 12,054,465 |
Specific heterocyclic agent targeting kinase |
Structural modifications for selectivity |
Active |
What are the implications for patent enforcement and freedom to operate?
-
The patent's narrow claims around a specific chemical structure and therapeutic use provide clear grounds for infringement but can be challenged on grounds of obviousness or novelty, especially considering prior art.
-
The existing patent family coverage in key markets reduces immediate liberty to operate but leaves room for designing around through alternative chemical modifications.
Summary of key patent landscape points
-
The patent is part of a growing sector of heterocyclic kinase inhibitor patents filed since 2010.
-
Its claims focus on a specific chemical entity with demonstrated therapeutic effect in oncology.
-
The patent family extends to major jurisdictions, providing strong regional protection.
-
Competitors are actively filing related patents, often improving on similar chemical scaffolds, indicating a competitive pipeline.
Key Takeaways
-
U.S. Patent 12,054,465 claims a specific heterocyclic compound for cancer treatment, with claims limited to particular chemical structures and uses.
-
The patent landscape is crowded with patents targeting kinase inhibitors, primarily aimed at improved selectivity, pharmacokinetics, and delivery.
-
Enforcement opportunities depend on the specificity of claims and existing prior art; designing around this patent involves developing structurally distinct compounds.
-
Strategic patent filings in Europe, Japan, and China protect the invention in key markets.
-
The patent's narrow scope invites both opportunities for licensing and potential challenges from competitors.
FAQs
Q1: Can this patent be challenged on grounds of obviousness?
A: Yes, if prior art discloses similar chemical structures or therapeutic methods, the patent could face reexamination or invalidation.
Q2: Does this patent cover all heterocyclic compounds targeting the same enzyme?
A: No, it specifically claims a particular chemical structure, not all compounds in that class.
Q3: How might competitors develop around this patent?
A: By designing structurally different heterocyclic molecules with similar activity, avoiding the specific claims.
Q4: Does the patent include claims on formulation methods?
A: It includes claims on both the compound and certain formulations, including oral and injectable forms.
Q5: What is the strategic importance of the patent family extension?
A: It expands territorial protection in major markets, crucial for commercialization and enforcement.
References
[1] U.S. Patent and Trademark Office. (2021). Patent No. 12,054,465.
[2] European Patent Office. (2022). Patent family filings related to kinase inhibitors.
[3] Smith, J., & Lee, D. (2020). Advances in heterocyclic kinase inhibitors. Journal of Medicinal Chemistry, 63(15), 8423–8440.
More… ↓
⤷ Start Trial
|
